Semaglutide and tirzepatide come up constantly in weight-loss conversations, and patients often ask us which one is "better." That's the wrong question. They work differently, cost differently, and fit differently depending on your health history and what your provider observes in your assessment. Here's what actually separates them, so you can have an informed conversation instead of guessing.
The mechanism difference
Semaglutide works through a single pathway: GLP-1. It mimics a hormone your gut naturally releases, slowing digestion, reducing appetite, and helping regulate blood sugar. It's the better-established of the two, with a longer track record in both diabetes care and weight management.
Tirzepatide works through two pathways: GLP-1 and GIP, a second gut hormone involved in insulin release and fat metabolism. Acting on both pathways at once is why some patients see a stronger response on tirzepatide, though individual response varies widely and results are never guaranteed for either medication. Neither one is automatically the right answer. Some patients respond well to semaglutide and never need to consider tirzepatide at all.
How providers choose
During your assessment, your provider looks at several things before recommending either option: your current weight and goals, any prior GLP-1 use and how you tolerated it, other health conditions like diabetes or reflux, and any medications you're currently taking. Someone new to GLP-1 medications is often started on semaglutide first, simply because it has the longer history and a gentler introduction for most people. Someone who has plateaued on semaglutide, or who has specific metabolic goals, may be a better fit for tirzepatide. Your provider makes this call, not a quiz result and not a preference you state without clinical context.
The cost difference
Cost is a real factor and we'd rather be upfront about it than bury it in fine print. Our semaglutide program starts from $99 per month. Our tirzepatide program starts from $249 per month. Both prices include your provider visit, medication when prescribed, dose titration, monthly check-ins, and shipping, with no insurance billed and cancel anytime. If you're deciding between the two partly on budget, that's a completely reasonable factor to bring up with your provider directly. It won't change their clinical judgment, but it's worth having on the table early.
Side-effect profiles
Both medications share the same general side-effect category: gastrointestinal symptoms like nausea, constipation, or reflux, especially as your dose increases. Because tirzepatide acts on two pathways instead of one, some patients report a somewhat different early adjustment period, though this varies enough person to person that it's not something we'd generalize into a rule. Both require the same careful, gradual dose titration for the same reason, to give your digestive system time to adjust before asking more of it. Your provider reviews the specific risks of whichever medication you're prescribed, and message-based check-ins mean you're never guessing alone if something feels off.
Switching between them
Patients switch in both directions, and it's a normal part of ongoing care, not a sign that something went wrong. Common reasons include reaching a plateau, tolerating side effects poorly, or wanting to try a different approach after months on one medication. If you're already on a GLP-1 through another provider and considering a switch, tell us your current medication and dose during your assessment. Your Medical Arts provider will review it and determine whether continuing at the same dose, adjusting, or switching medications makes the most sense for you.
Side-by-side comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 pathway | GLP-1 + GIP pathways |
| Track record | Longer-established | Newer, growing use |
| Typical starting point | Often first-line for new patients | Often considered after semaglutide, or for specific goals |
| Program price | From $99/mo | From $249/mo |
| Dosing | Once weekly, titrated gradually | Once weekly, titrated gradually |
| Common side effects | Nausea, constipation, reflux | Nausea, constipation, reflux |
| Includes | Provider visit, titration, monthly check-ins, shipping | Provider visit, titration, monthly check-ins, shipping |
Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed provider based on your individual health history. Results vary and are not guaranteed.
Your provider decides
We could tell you which one sounds better in a headline, but that's not how good medical care works, and it's not what we're building here. Your assessment gives a licensed provider the information they need to recommend semaglutide, tirzepatide, or neither, based on your actual health, not a marketing preference. That's the whole point of physician-supervised care: someone qualified is making the call, and you're never guessing alone.
If you're ready to find out which program, if any, a provider would recommend for you, the assessment takes about two minutes and there's no cost to check.